P
PERSONALIS INC
NASDAQ: PSNL (Personalis, Inc.)
Last update: 14 minutes ago16.57
0.00 (0.00%)
| Previous Close | 16.57 |
| Volume | 200,521 |
| Price / Sales | 22.93 |
| Price / Book | 7.43 |
| 52 Weeks Range |
| Profit Margin | -98.10% |
| Operating Margin (TTM) | -85.88% |
| Diluted EPS (TTM) | -1.29 |
| Quarterly Revenue Growth (YOY) | 5.50% |
| Total Debt/Equity (MRQ) | 21.81% |
| Current Ratio (MRQ) | 6.91 |
| Operating Cash Flow (TTM) | -42.70 M |
| Levered Free Cash Flow (TTM) | -23.09 M |
| Return on Assets (TTM) | -17.90% |
| Return on Equity (TTM) | -51.25% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Personalis, Inc. | Mixed | Bullish |
AIStockmoo Score
-0.9
| Analyst Consensus | NA |
| Insider Activity | -3.0 |
| Price Volatility | -3.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | -0.88 |
|
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 31.49% |
| % Held by Institutions | 46.11% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Merck & Co., Inc. | 30 Jun 2026 | 14,044,943 |
| Ark Investment Management Llc | 30 Jun 2026 | 8,271,339 |
| Lightspeed Management Company, L.L.C. | 30 Jun 2026 | 6,101,850 |
| Ameriprise Financial Inc | 30 Jun 2026 | 6,086,315 |
| Deep Track Capital, Lp | 30 Jun 2026 | 4,000,000 |
| Aberdeen Group Plc | 30 Jun 2026 | 3,747,290 |
| Casdin Capital, Llc | 30 Jun 2026 | 2,550,000 |
| Kennedy Capital Management Llc | 30 Jun 2026 | 2,364,282 |
| Bank Of America Corp /De/ | 30 Jun 2026 | 1,820,541 |
| Aigh Capital Management Llc | 30 Jun 2026 | 1,715,000 |
| Blue Water Life Science Advisors, Lp | 30 Jun 2026 | 1,676,300 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CHEN RICHARD | - | 16.40 | -3,998 | -65,567 |
| HALL CHRISTOPHER M | - | 16.40 | -7,459 | -122,328 |
| MOORE STEPHEN MICHAEL | - | 16.40 | -2,068 | -33,915 |
| TACHIBANA AARON | - | 16.40 | -2,931 | -48,068 |
| Aggregate Net Quantity | -16,456 | |||
| Aggregate Net Value ($) | -269,878 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 16.40 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TACHIBANA AARON | Officer | 18 Sep 2026 | Sell (-) | 2,931 | 16.40 | 48,068 |
| HALL CHRISTOPHER M | Officer | 18 Sep 2026 | Sell (-) | 7,459 | 16.40 | 122,328 |
| MOORE STEPHEN MICHAEL | Officer | 18 Sep 2026 | Sell (-) | 2,068 | 16.40 | 33,915 |
| CHEN RICHARD | Officer | 18 Sep 2026 | Sell (-) | 3,998 | 16.40 | 65,567 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |